Medtronic's Itrel 3 cleared in US:
This article was originally published in Clinica
The US FDA has cleared Medtronic's Itrel 3 spinal cord stimulation system for control of chronic pain for marketing. Sales are expected to begin in November. The system, which succeeds the Itrel and Itrel 2 implantable systems, was launched in Europe in July and has been approved for marketing in Canada and Australia (see Clinica No 663, p 20).